Ratio de rentabilidad sobre activos (ROA)
desde 2005
Cálculo
Vertex Pharmaceuticals Inc., ROA, tendencias a largo plazocálculo
| ROA | = | 100 | × | Utilidad (pérdida) neta1 | ÷ | Activos totales1 | |
|---|---|---|---|---|---|---|---|
| 31 dic. 2023 | 15.92% | = | 100 | × | 3,619,600) | ÷ | 22,730,200) |
| 31 dic. 2022 | 18.30% | = | 100 | × | 3,322,000) | ÷ | 18,150,900) |
| 31 dic. 2021 | 17.44% | = | 100 | × | 2,342,100) | ÷ | 13,432,500) |
| 31 dic. 2020 | 23.07% | = | 100 | × | 2,711,647) | ÷ | 11,751,808) |
| 31 dic. 2019 | 14.15% | = | 100 | × | 1,176,810) | ÷ | 8,318,465) |
| 31 dic. 2018 | 33.57% | = | 100 | × | 2,096,896) | ÷ | 6,245,898) |
| 31 dic. 2017 | 7.43% | = | 100 | × | 263,484) | ÷ | 3,546,014) |
| 31 dic. 2016 | -3.87% | = | 100 | × | (112,052) | ÷ | 2,896,787) |
| 31 dic. 2015 | -22.26% | = | 100 | × | (556,334) | ÷ | 2,498,875) |
| 31 dic. 2014 | -31.63% | = | 100 | × | (738,555) | ÷ | 2,334,679) |
| 31 dic. 2013 | -19.19% | = | 100 | × | (445,028) | ÷ | 2,319,041) |
| 31 dic. 2012 | -3.88% | = | 100 | × | (107,032) | ÷ | 2,759,288) |
| 31 dic. 2011 | 1.34% | = | 100 | × | 29,574) | ÷ | 2,204,280) |
| 31 dic. 2010 | -43.74% | = | 100 | × | (754,626) | ÷ | 1,725,446) |
| 31 dic. 2009 | -32.84% | = | 100 | × | (642,178) | ÷ | 1,955,488) |
| 31 dic. 2008 | -46.90% | = | 100 | × | (459,851) | ÷ | 980,479) |
| 31 dic. 2007 | -65.05% | = | 100 | × | (391,279) | ÷ | 601,477) |
| 31 dic. 2006 | -22.45% | = | 100 | × | (206,891) | ÷ | 921,579) |
| 31 dic. 2005 | -37.05% | = | 100 | × | (203,417) | ÷ | 548,998) |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
1 US$ en miles
Comparación con la competencia
Vertex Pharmaceuticals Inc., ROA, tendencias a largo plazo, comparación con los competidores
| Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Zoetis Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 dic. 2023 | 15.92% | 3.61% | 6.91% | 8.43% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 6.07% | 16.41% |
| 31 dic. 2022 | 18.30% | 8.53% | 10.06% | 6.53% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 7.15% | 14.16% |
| 31 dic. 2021 | 17.44% | 7.88% | 9.63% | 6.40% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 8.12% | 14.65% |
| 31 dic. 2020 | 23.07% | 3.07% | 11.54% | -7.61% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 9.23% | 12.04% |
| 31 dic. 2019 | 14.15% | 8.84% | 13.13% | 2.65% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 6.33% | 12.99% |
| 31 dic. 2018 | 33.57% | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% | 13.25% |
| 31 dic. 2017 | 7.43% | 7.50% | 2.48% | 3.00% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 3.93% | 10.06% |
| 31 dic. 2016 | -3.87% | 9.01% | 9.95% | 13.22% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | 4.40% | 10.73% |
| 31 dic. 2015 | -22.26% | 9.70% | 9.69% | 4.93% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | 4.83% | 4.28% |
| 31 dic. 2014 | -31.63% | 6.44% | 7.47% | 5.94% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | 4.42% | 8.82% |
| 31 dic. 2013 | -19.19% | 14.14% | 7.68% | 6.64% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | 4.00% | 7.69% |
| 31 dic. 2012 | -3.88% | 19.53% | 8.00% | 5.46% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | 4.29% | 6.96% |
| 31 dic. 2011 | 1.34% | — | 7.54% | 11.25% | 7.25% | 12.92% | 16.20% | 8.51% | 5.97% | 5.32% | -16.75% | 4.96% | — |
| 31 dic. 2010 | -43.74% | — | 10.64% | 9.98% | 8.07% | 16.35% | 25.03% | 12.96% | 0.81% | 4.23% | -9.59% | 4.85% | — |
| 31 dic. 2009 | -32.84% | — | 11.62% | 34.22% | 5.88% | 15.76% | 27.18% | 12.95% | 11.51% | 4.05% | -9.15% | 3.93% | — |
| 31 dic. 2008 | -46.90% | — | 11.51% | 17.76% | 7.53% | -7.09% | 28.65% | 15.25% | 16.54% | 7.29% | -12.34% | 4.71% | — |
| 31 dic. 2007 | -65.05% | — | 9.14% | 8.27% | 7.84% | 11.02% | 27.68% | 13.06% | 6.77% | 7.07% | -11.28% | 3.59% | — |
| 31 dic. 2006 | -22.45% | — | 8.73% | 6.20% | 8.72% | 12.13% | -29.12% | 15.67% | 9.95% | 16.84% | -17.49% | 0.79% | — |
| 31 dic. 2005 | -37.05% | — | 12.54% | 10.66% | 9.80% | 8.05% | 21.62% | 17.94% | 10.33% | 6.88% | -22.54% | 5.25% | — |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
Comparación con el sector industrial: Productos farmacéuticos, biotecnología y ciencias de la vida
Vertex Pharmaceuticals Inc., ROA, tendencias a largo plazo, comparación con el sector industrial: productos farmacéuticos, biotecnología y ciencias de la vida
| Vertex Pharmaceuticals Inc. | Productos farmacéuticos, biotecnología y ciencias de la vida | |
|---|---|---|
| 31 dic. 2023 | 15.92% | 7.19% |
| 31 dic. 2022 | 18.30% | 10.59% |
| 31 dic. 2021 | 17.44% | 10.39% |
| 31 dic. 2020 | 23.07% | 5.34% |
| 31 dic. 2019 | 14.15% | 9.02% |
| 31 dic. 2018 | 33.57% | 8.84% |
| 31 dic. 2017 | 7.43% | 5.32% |
| 31 dic. 2016 | -3.87% | 8.68% |
| 31 dic. 2015 | -22.26% | 8.98% |
| 31 dic. 2014 | -31.63% | 9.58% |
| 31 dic. 2013 | -19.19% | 9.54% |
| 31 dic. 2012 | -3.88% | 8.34% |
| 31 dic. 2011 | 1.34% | 7.32% |
| 31 dic. 2010 | -43.74% | 7.23% |
| 31 dic. 2009 | -32.84% | 10.17% |
| 31 dic. 2008 | -46.90% | 10.52% |
| 31 dic. 2007 | -65.05% | 8.98% |
| 31 dic. 2006 | -22.45% | 12.00% |
| 31 dic. 2005 | -37.05% | 10.50% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
Comparación con la industria: Atención médica
Vertex Pharmaceuticals Inc., ROA, tendencias a largo plazo, comparación con la industria: atención médica
| Vertex Pharmaceuticals Inc. | Atención médica | |
|---|---|---|
| 31 dic. 2023 | 15.92% | 6.42% |
| 31 dic. 2022 | 18.30% | 8.35% |
| 31 dic. 2021 | 17.44% | 8.24% |
| 31 dic. 2020 | 23.07% | 5.46% |
| 31 dic. 2019 | 14.15% | 7.22% |
| 31 dic. 2018 | 33.57% | 6.17% |
| 31 dic. 2017 | 7.43% | 5.34% |
| 31 dic. 2016 | -3.87% | 6.95% |
| 31 dic. 2015 | -22.26% | 7.35% |
| 31 dic. 2014 | -31.63% | 8.18% |
| 31 dic. 2013 | -19.19% | 8.28% |
| 31 dic. 2012 | -3.88% | 7.68% |
| 31 dic. 2011 | 1.34% | 7.00% |
| 31 dic. 2010 | -43.74% | 6.99% |
| 31 dic. 2009 | -32.84% | 9.19% |
| 31 dic. 2008 | -46.90% | 8.56% |
| 31 dic. 2007 | -65.05% | 8.18% |
| 31 dic. 2006 | -22.45% | 9.77% |
| 31 dic. 2005 | -37.05% | 9.09% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).